ALIMERA SCIENCES INC (ALIM)
US0162592028 - Common Stock
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy...
ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023
ALIM stock results show that Alimera Sciences beat on revenue for the fourth quarter of 2023.
ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ:ALIM) just reported results for the fourth quarter of ...
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ...
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment...
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose...
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose...
Alimera Appoints Maggie A. Pax to Its Board of Directors
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...
Alimera Sciences Reports Third Quarter 2023 Results
Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful...
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
Dr. Philip Ashman Appointed as President of International Operations...
Alimera Sciences Reports Second Quarter 2023 Results
Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5...
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
Conference Call to be held the same day at 9:00am Eastern Time...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off the final day of the trading week with a breakdown of the biggest pre-market stock movers for Friday!
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Alimera Sciences (ALIM) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (EYPT).
Alimera stock jumps on deal with EyePoint stock for Yutiq
Nano-cap pharma Alimera Sciences (ALIM) added ~48% pre-market Thursday after announcing the acquisition of U.S
Alimera Acquires U.S. Commercial Rights to YUTIQ®
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20...
Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
ATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be...
Alimera Sciences Reports First Quarter 2023 Results
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and...
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
Conference Call to be held the same day at 9:00am Eastern Time...
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists...